Rituximab therapy in a patient with steroid-refractory bird fancier's lung

E. Ceci Bonello (Naxxar, Malta)

Source: International Congress 2019 – CCC Interstitial lung diseases
Session: CCC Interstitial lung diseases
Session type: Challenging clinical cases
Number: 3503
Disease area: Interstitial lung diseases

WebcastSlide presentationPDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Ceci Bonello (Naxxar, Malta). Rituximab therapy in a patient with steroid-refractory bird fancier's lung. International Congress 2019 – CCC Interstitial lung diseases

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Granulomatous lung disease in lymphoma patient after rituximab treatment
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020

Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014

Cyclophosphamide in steroid-refractory hypersensitivity pneumonitis and non-classifiable interstitial lung disease
Source: International Congress 2017 – Novel and old entities
Year: 2017

Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013

Wegener's granulomatosis after Montelukast in patient not receiving systemic steroid treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 65s
Year: 2002

Rituximab for the treatment of chronic hypersensitivity pneumonitis
Source: International Congress 2015 – Interstitial lung diseases I
Year: 2015

Hypersensitivity pneumonitis secondary to lovebirds: a new cause of bird fancier's disease
Source: Eur Respir J 2008; 32: 517-521
Year: 2008

Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD
Source: International Congress 2016 – Connective tissue disorders
Year: 2016

Pulmonary tuberculosis in hodgkin's disease after high dose chemotherapy
Source: Annual Congress 2003 - Clinical aspects of tuberculosis
Year: 2003

Infliximab for treating sarcoidosis, portuguese experience
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009

Tacrolimus for antisynthetase syndrome with interstitial lung disease?
Source: Eur Respir J 2008; 32: 244-245
Year: 2008

Severe fibrotic lung disease – How much therapy is too much therapy?
Source: Annual Congress 2008 - Clinical Grand Round - an interactive session
Year: 2008

Pneumococcal vaccination in interstitial lung disease patients receiving systemic immunosuppressive treatment
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis  
Year: 2017

Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis
Source: Eur Respir J 2002; 20: Suppl. 38, 587s
Year: 2002

Infliximab: An effective rescue therapy in refractory extra-pulmonary sarcoidosis
Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis
Year: 2013

Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis
Source: Annual Congress 2004 - Fibrosing lung diseases
Year: 2004

Rituximab improves interstitial lung disease in rheumatoid arthritis patients
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017

Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011

Rituximab treatment of a case of anti-syntetase syndrome with severe interstitial lung disease and acute respiratory failure
Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease
Year: 2010

Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016